[Treatment of nasopharyngeal cancer with recombinant gamma interferon (IFN). A report based on 2 patients].
Patients with advanced NPC and tumour relapses were efficiently treated with recombined gamma-interferon in some instances. The authors report on two selected cases with elevated EBV titres who belonged to the "high-risk group" and had an unfavourable prognosis. Both patients were treated with gamma-interferon over a period of 6 months and the EBV titres decreased. No relapses have been observed until now. Radiation therapy (RT) is the treatment of choice in NPC. Chemotherapy does not show any advantage in respect of relapse-free survival and overall survival. Interferon seems to be an efficient therapy in selected cases. Questions regarding the effectiveness, the dosage and side effects of the individual classes of interferons are still unclear and should be an important task for further research.
D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*
D011994:Recombinant Proteins; D007371:Interferon-gamma
Die Behandlung des Nasopharynxkarzinoms mit rekombinantem Gamma-Interferon (IFN). Eine Fallbeschreibung anhand von zwei Patienten.